Citigroup Inc. grew its stake in shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) by 178.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 73,951 shares of the biotechnology company’s stock after buying an additional 47,347 shares during the period. Citigroup Inc. owned 0.24% of Spark Therapeutics worth $4,418,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA increased its position in Spark Therapeutics by 530.1% during the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after buying an additional 2,449 shares in the last quarter. Pacad Investment Ltd. increased its position in Spark Therapeutics by 75.0% during the second quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after buying an additional 1,500 shares in the last quarter. Highbridge Capital Management LLC purchased a new position in Spark Therapeutics during the first quarter worth $227,000. KCG Holdings Inc. increased its position in Spark Therapeutics by 9.4% during the first quarter. KCG Holdings Inc. now owns 6,247 shares of the biotechnology company’s stock worth $333,000 after buying an additional 538 shares in the last quarter. Finally, Legal & General Group Plc increased its position in Spark Therapeutics by 16.8% during the second quarter. Legal & General Group Plc now owns 8,931 shares of the biotechnology company’s stock worth $532,000 after buying an additional 1,286 shares in the last quarter. 91.01% of the stock is owned by institutional investors.

Several equities analysts have weighed in on the company. Royal Bank Of Canada assumed coverage on Spark Therapeutics in a research report on Thursday, September 14th. They set an “outperform” rating and a $100.00 price target for the company. Barclays PLC assumed coverage on Spark Therapeutics in a research report on Wednesday, September 6th. They set an “overweight” rating and a $104.00 price target for the company. BidaskClub raised Spark Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, August 26th. Cantor Fitzgerald reissued a “buy” rating on shares of Spark Therapeutics in a research report on Friday, August 25th. Finally, Evercore ISI assumed coverage on Spark Therapeutics in a research report on Wednesday, August 16th. They set an “in-line” rating and a $83.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and fifteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $84.78.

WARNING: “Spark Therapeutics, Inc. (ONCE) Stake Increased by Citigroup Inc.” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/09/24/spark-therapeutics-inc-once-stake-increased-by-citigroup-inc.html.

In other Spark Therapeutics news, CFO Stephen W. Webster sold 2,337 shares of the stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $71.12, for a total value of $166,207.44. Following the sale, the chief financial officer now owns 4,837 shares of the company’s stock, valued at approximately $344,007.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Daniel Faga sold 1,500 shares of the stock in a transaction dated Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total value of $127,500.00. Following the completion of the sale, the insider now directly owns 1,500 shares in the company, valued at approximately $127,500. The disclosure for this sale can be found here. Insiders sold a total of 348,364 shares of company stock worth $25,269,986 in the last ninety days. 7.30% of the stock is owned by corporate insiders.

Shares of Spark Therapeutics, Inc. (NASDAQ ONCE) opened at 85.15 on Friday. The stock has a 50 day moving average price of $82.71 and a 200-day moving average price of $82.71. Spark Therapeutics, Inc. has a 12 month low of $35.07 and a 12 month high of $87.00. The stock’s market cap is $2.66 billion.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.75) by ($0.14). The company had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.33 million. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. Spark Therapeutics’s revenue for the quarter was up 14.7% on a year-over-year basis. During the same period in the prior year, the business earned ($1.04) EPS. On average, analysts forecast that Spark Therapeutics, Inc. will post ($7.69) EPS for the current fiscal year.

Spark Therapeutics Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics, Inc. (NASDAQ:ONCE).

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.